ε-Aminocaproic acid inhibition of fibrinolysis in vitro

Should the 'therapeutic' concentration be reconsidered?

Vance G Nielsen, Lana Cankovic, Brad L. Steenwyk

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

The therapeutic concentration of ε-aminocaproic acid (EACA) has been 130 μg/ml or greater for nearly 50 years. We tested the effects on clot growth/disintegration of EACA with a plasmatic model of hyperfibrinolysis in vitro. Human plasma was exposed to 1000 U/ml tissue-type plasminogen activator containing 0, 13, 65 or 130 μg/ml EACA, with clot growth/disintegration kinetics quantified via thrombelastography. Data were analyzed with one-way analysis of variance or Kruskal-Wallis analysis of variance as appropriate. Exposure of plasma to 1000 U/ml tissue-type plasminogen activator resulted in a brief-lived clot, lasting 2 min. EACA at all concentrations tested significantly increased the rate of clot growth compared with samples with 0 μg/ml EACA. Clot strength was significantly increased by EACA in a concentration-dependent fashion. Similarly, EACA significantly prolonged the time of onset of clot lysis and decreased the rate of lysis. Samples with 130 μg/ml EACA had no sign of lysis present for 30 min. Subtherapeutic to therapeutic concentrations of EACA significantly attenuated or abolished fibrinolysis in the presence of a concentration of tissue-type plasminogen activator more than 2000-fold that encountered systemically during cardiopulmonary bypass. Further clinical investigation is warranted to determine whether smaller concentrations of EACA could provide a reduction in bleeding with a concomitant decrease in thrombotic complications.

Original languageEnglish (US)
Pages (from-to)35-39
Number of pages5
JournalBlood Coagulation and Fibrinolysis
Volume18
Issue number1
DOIs
StatePublished - Jan 2007
Externally publishedYes

Fingerprint

Aminocaproic Acid
Fibrinolysis
Tissue Plasminogen Activator
Analysis of Variance
Growth
Fibrin Clot Lysis Time
Thrombelastography
Cardiopulmonary Bypass
Therapeutics
Hemorrhage
In Vitro Techniques

Keywords

  • ε-aminocaproic acid
  • Coagulation
  • Fibrinolysis
  • Measurement techniques
  • Thrombelastography
  • Tissue type plasminogen activator

ASJC Scopus subject areas

  • Hematology

Cite this

ε-Aminocaproic acid inhibition of fibrinolysis in vitro : Should the 'therapeutic' concentration be reconsidered? / Nielsen, Vance G; Cankovic, Lana; Steenwyk, Brad L.

In: Blood Coagulation and Fibrinolysis, Vol. 18, No. 1, 01.2007, p. 35-39.

Research output: Contribution to journalArticle

@article{70e9949dc4ff4f9cbd19b3c3aa27a104,
title = "ε-Aminocaproic acid inhibition of fibrinolysis in vitro: Should the 'therapeutic' concentration be reconsidered?",
abstract = "The therapeutic concentration of ε-aminocaproic acid (EACA) has been 130 μg/ml or greater for nearly 50 years. We tested the effects on clot growth/disintegration of EACA with a plasmatic model of hyperfibrinolysis in vitro. Human plasma was exposed to 1000 U/ml tissue-type plasminogen activator containing 0, 13, 65 or 130 μg/ml EACA, with clot growth/disintegration kinetics quantified via thrombelastography. Data were analyzed with one-way analysis of variance or Kruskal-Wallis analysis of variance as appropriate. Exposure of plasma to 1000 U/ml tissue-type plasminogen activator resulted in a brief-lived clot, lasting 2 min. EACA at all concentrations tested significantly increased the rate of clot growth compared with samples with 0 μg/ml EACA. Clot strength was significantly increased by EACA in a concentration-dependent fashion. Similarly, EACA significantly prolonged the time of onset of clot lysis and decreased the rate of lysis. Samples with 130 μg/ml EACA had no sign of lysis present for 30 min. Subtherapeutic to therapeutic concentrations of EACA significantly attenuated or abolished fibrinolysis in the presence of a concentration of tissue-type plasminogen activator more than 2000-fold that encountered systemically during cardiopulmonary bypass. Further clinical investigation is warranted to determine whether smaller concentrations of EACA could provide a reduction in bleeding with a concomitant decrease in thrombotic complications.",
keywords = "ε-aminocaproic acid, Coagulation, Fibrinolysis, Measurement techniques, Thrombelastography, Tissue type plasminogen activator",
author = "Nielsen, {Vance G} and Lana Cankovic and Steenwyk, {Brad L.}",
year = "2007",
month = "1",
doi = "10.1097/MBC.0b013e328010a359",
language = "English (US)",
volume = "18",
pages = "35--39",
journal = "Blood Coagulation and Fibrinolysis",
issn = "0957-5235",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - ε-Aminocaproic acid inhibition of fibrinolysis in vitro

T2 - Should the 'therapeutic' concentration be reconsidered?

AU - Nielsen, Vance G

AU - Cankovic, Lana

AU - Steenwyk, Brad L.

PY - 2007/1

Y1 - 2007/1

N2 - The therapeutic concentration of ε-aminocaproic acid (EACA) has been 130 μg/ml or greater for nearly 50 years. We tested the effects on clot growth/disintegration of EACA with a plasmatic model of hyperfibrinolysis in vitro. Human plasma was exposed to 1000 U/ml tissue-type plasminogen activator containing 0, 13, 65 or 130 μg/ml EACA, with clot growth/disintegration kinetics quantified via thrombelastography. Data were analyzed with one-way analysis of variance or Kruskal-Wallis analysis of variance as appropriate. Exposure of plasma to 1000 U/ml tissue-type plasminogen activator resulted in a brief-lived clot, lasting 2 min. EACA at all concentrations tested significantly increased the rate of clot growth compared with samples with 0 μg/ml EACA. Clot strength was significantly increased by EACA in a concentration-dependent fashion. Similarly, EACA significantly prolonged the time of onset of clot lysis and decreased the rate of lysis. Samples with 130 μg/ml EACA had no sign of lysis present for 30 min. Subtherapeutic to therapeutic concentrations of EACA significantly attenuated or abolished fibrinolysis in the presence of a concentration of tissue-type plasminogen activator more than 2000-fold that encountered systemically during cardiopulmonary bypass. Further clinical investigation is warranted to determine whether smaller concentrations of EACA could provide a reduction in bleeding with a concomitant decrease in thrombotic complications.

AB - The therapeutic concentration of ε-aminocaproic acid (EACA) has been 130 μg/ml or greater for nearly 50 years. We tested the effects on clot growth/disintegration of EACA with a plasmatic model of hyperfibrinolysis in vitro. Human plasma was exposed to 1000 U/ml tissue-type plasminogen activator containing 0, 13, 65 or 130 μg/ml EACA, with clot growth/disintegration kinetics quantified via thrombelastography. Data were analyzed with one-way analysis of variance or Kruskal-Wallis analysis of variance as appropriate. Exposure of plasma to 1000 U/ml tissue-type plasminogen activator resulted in a brief-lived clot, lasting 2 min. EACA at all concentrations tested significantly increased the rate of clot growth compared with samples with 0 μg/ml EACA. Clot strength was significantly increased by EACA in a concentration-dependent fashion. Similarly, EACA significantly prolonged the time of onset of clot lysis and decreased the rate of lysis. Samples with 130 μg/ml EACA had no sign of lysis present for 30 min. Subtherapeutic to therapeutic concentrations of EACA significantly attenuated or abolished fibrinolysis in the presence of a concentration of tissue-type plasminogen activator more than 2000-fold that encountered systemically during cardiopulmonary bypass. Further clinical investigation is warranted to determine whether smaller concentrations of EACA could provide a reduction in bleeding with a concomitant decrease in thrombotic complications.

KW - ε-aminocaproic acid

KW - Coagulation

KW - Fibrinolysis

KW - Measurement techniques

KW - Thrombelastography

KW - Tissue type plasminogen activator

UR - http://www.scopus.com/inward/record.url?scp=33845807903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845807903&partnerID=8YFLogxK

U2 - 10.1097/MBC.0b013e328010a359

DO - 10.1097/MBC.0b013e328010a359

M3 - Article

VL - 18

SP - 35

EP - 39

JO - Blood Coagulation and Fibrinolysis

JF - Blood Coagulation and Fibrinolysis

SN - 0957-5235

IS - 1

ER -